Recent News

ASTRO 2022: Assessing Sexual Dysfunction After Brachytherapy for Genitourinary Cancers

ASTRO 2022: Sequencing of Short-Term Androgen-Deprivation Therapy With Radiotherapy for Prostate Cancer

ASTRO 2022: Salvage Radiotherapy Plus Enzalutamide for High-Risk Prostate Cancer After Prostatectomy

SITC 2022: Phase II Study of Vudalimab for Metastatic Castration-Resistant Prostate Cancer

ASTRO 2022: Hypofractionated Radiotherapy for High-Risk Prostate Cancer

ASTRO 2022: Using 24-Gene Score to Predict Outcomes With Salvage Radiotherapy After Radical Prostatectomy

ASTRO 2022: Is There a Correlation Between PSA Screening and Subsequent Metastatic Prostate Cancer?

ASTRO 2022: Combining Hormone Therapy and Metastasis-Directed Radiotherapy for Advanced Prostate Cancer

ASTRO 2022: Multimodal Deep Learning Versus NCCN Risk Stratification of Prostate Cancer

ASTRO 2022: PSMA PET/CT and Its Impact on Prostate Cancer Salvage Radiation Therapy Management

Targeted Imaging With PSMA Tracer May Alter Treatment Plans for Some Patients With Prostate Cancer

Oligometastatic Prostate Cancer: Do Genomic Alterations Have Prognostic Value?

BET Inhibitor Under Study in Metastatic Castration-Resistant Prostate Cancer

ASCO Quality 2022: An Education Initiative That Aims to Improve Equity in Prostate Cancer Screening

Genomic Classifiers as Prognostic Factors for Androgen-Deprivation Therapy for Advanced Prostate Cancer

Targeting Myeloid Chemotaxis in Resistant Metastatic Prostate Cancer

ASCO Quality 2022: Tailored Self-Managed Care for Survivors of Prostate Cancer

Biomarker Analysis From PROpel Trial of Abiraterone Plus Olaparib in Advanced Prostate Cancer

African Ancestry and Genetic Variants in Prostate Tumors

ESMO 2022: Pembrolizumab Plus Olaparib Under Study in Metastatic Castration-Resistant Prostate Cancer

ESMO 2022: Adding Hormonal Therapy to the Treatment Mix in Biochemically Relapsed Prostate Cancer

ESMO 2022: Inhibitor of CYP11A Under Study in Metastatic Castration-Resistant Prostate Cancer

Group Exercise for Men With Prostate Cancer Undergoing Androgen-Deprivation Therapy

ESMO 2022: Dosing Adjustments With Cabazitaxel in Older Patients With Prostate Cancer

ESMO 2022: Using 8-Month PSA Values From PEACE-1 to Predict Prostate Cancer Survival

Assessing Genetic Risk in Primary Care May Lead to Earlier Diagnosis for Patients at Risk for Prostate Cancer

Can the Corticosteroid Betamethasone Improve Outcomes With Radiation Therapy for Prostate Cancer?

Using Virtual Reality Models to Improve Surgical Decision-Making in Prostate Cancer

FDA Approves Darolutamide Combination for Metastatic Hormone-Sensitive Prostate Cancer

Genetic Evaluation of Castration-Resistant Prostate Cancer: Focus on CDK6 Expression

FDA Grants Priority Review to Olaparib-Based Combination for Metastatic Castration-Resistant Prostate Cancer

Randomized Trial to Focus on Lifestyle Changes During Radiotherapy for Prostate Cancer

Genomic Studies Offer Insight Into Progression of Prostate Cancer After Hormonal Therapy

Digital Health Coaching for Patients With Prostate Cancer: Findings of a Pilot Study

Combining Tyrosine Kinase and PD-L1 Inhibitors to Treat Metastatic Prostate Cancer

Using a Multimodal Artificial Intelligence System to Personalize Therapy for Prostate Cancer

Are LHRH Antagonists Indicated for Patients With Prostate Cancer at High Cardiovascular Risk?

What Can Be Learned From ctDNA About Treatment-Resistant Prostate Cancer? Researchers Say a Lot